Clinical Trial Update: Study to Evaluate the Efficacy and Safety of SPH3127 In Patients With Mild-moderate Essential Hypertension [Phase 3]

View source ↗

Summary

This entry notes the completion of a Phase 3 trial evaluating SPH3127 for mild-to-moderate essential hypertension, focusing on efficacy and safety endpoints.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Essential Hypertension

Drugs mentioned

• SPH3127

Snippet

Sponsor: Shanghai Pharmaceuticals Holding Co., Ltd | Conditions: Essential Hypertension | Phase 3 | Status: COMPLETED